Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 25;43(1):126-132.
doi: 10.5937/jomb0-45223.

The effect of different dose of heparin using in peripheral arteriovenous synchronous blood exchange transfusion for neonatal hyperbilirubinemia

Xueyun Guan  1 , Jing Guo  1 , Dongsu Xiao  1 , Zhong Wu  2
Affiliations

The effect of different dose of heparin using in peripheral arteriovenous synchronous blood exchange transfusion for neonatal hyperbilirubinemia

Xueyun Guan et al. J Med Biochem. .

Abstract
in English, Serbian

Background: To explore the optimal dosage of heparin in peripheral arteriovenous automatic synchronous exchange transfusion therapy for neonatal hyperbilirubinemia.

Methods: A total of 185 neonates received peripheral arteriovenous synchronous blood exchange transfusion for hyperbilirubinemia were enrolled from pediatric department of the Ganzhou People's Hospital between January 2018 and June 2020, which were randomly divided into four groups. On the basis of exchange transfusion, different dose of heparin was pumping at the bleeding site of artery (A: no heparin; B: 100 U/h heparin; C: 200 U/h heparin; D: 300 U/h heparin). The indexes of exchange transfusion efficacy, including total bilirubin conversion rate, indirect bilirubin conversion rate, hemoglobin concentration, the platelet number and APTT value was measured before and after therapy. The sites of artery puncture, the sites and rate of vascular occlusion were counted and analyzed.

Uvod: Cilj je bio da se istraži optimalna doza heparina u perifernoj arteriovenskoj automatskoj sinhronoj transfuzijskoj terapiji za neonatalnu hiperbilirubinemiju.

Metode: Ukupno 185 novorođenčadi primilo je perifernu arteriovensku sinhronu transfuziju krvi zbog hiperbilirubinemije sa pedijatrijskog odeljenja Narodne bolnice u Ganzhou između januara 2018. i juna 2020. godine, koji su nasumično podeljeni u četiri grupe. Na osnovu izmene transfuzije, različite doze heparina su pumpane na mestu krvarenja arterije (A: nema heparina; B: 100 U/h heparina; C: 200 U/h heparina; D: 300 U/h heparina). Indeksi efikasnosti razmene transfuzije, uključuju i stopu konverzije ukupnog bilirubina, stopu konverzije indirektnog bilirubina, koncentraciju hemoglobina, broj trombocita i vrednost APTT mereni su pre i posle terapije. Mesta punkcije arterija, mesta i stopa vaskularne okluzije su prebrojani i analizirani.

Rezultati: Nije bilo značajne razlike u stopi konverzije ukupnog bilirubina, stopi indirektne konverzije bilirubina, koncentraciji hemoglobina u broju trombocita i vrednosti APTT pre i posle transfuzije izmene između četiri grupe (P >0,05). Pored toga, nije bilo statističke značajnosti u mestima punkcije arterija između četiri grupe (P > 0,05). Utvrđena je značajna razlika u ukupnoj stopi vaskularne okluzije i stopi okluzije radijalne arterije između četiri grupe (P<0,05).

Zaključak: Različite doze heparina koje se koriste u perifernoj arteriovenskoj sinhronoj transfuziji krvi nisu uticale na terapijski efekat ili koagulacionu funkciju pacijenata, ali su mogle da smanje stopu okluzije u zavisnosti od mesta arterijske punkcije.

Keywords: heparin; hyperbilirubinemia; neonatal; peripheral arteriovenous synchronous blood exchange transfusion.

PubMed Disclaimer

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.

Figures

Figure 1
Figure 1. The results of measure analysis of variance for comparison of total bilirubin conversion rate, indirect bilirubin conversion rate, hemoglobin concentration before ET and hemoglobin concentration after ET. There was no between the four groups (P>0.05). Measurements are expressed as mean ± standard deviation. ET: exchange transfusion; A: no heparin group; B 100 U/h heparin group; C: 200 U/h heparin group; D: 300 U/h heparin group.
Figure 2
Figure 2. The results of measure analysis of variance for comparison of platelet number before ET, platelet number after ET, APTT value before ET, APTT value after ET. There was no between the four groups (P >0.05). Measurements are expressed as mean ± standard deviation. ET: exchange transfusion; A: no heparin group; B 100 U/h heparin group; C: 200 U/h heparin group; D: 300 U/h heparin group.
See this image and copyright information in PMC

References

    1. Yu B, Hu F. Exploration of the pathogenic factors of neonatal jaundice and the clinical effect of blue phototherapy. Am J Transl Res. 2021;13(6):6802. - PMC - PubMed
    1. Olusanya B O, Kaplan M, Hansen T. Neonatal hyperbilirubinaemia: A global perspective Lancet Child Adolesc. 2018;2(8):610. doi: 10.1016/s2352-4642(18)30139-1. - DOI - PubMed
    1. Boskabadi H, Rakhshanizadeh F, Zakerihamidi M. Evaluation of Maternal Risk Factors in Neonatal Hyperbilirubinemia. Arch Iran Med. 2020;23(2):128. - PubMed
    1. Newman T B, Meisels M J. Evaluation and treatman of jaundice in term newborn: A kinder gentler approach. Pediatrics. 1992;89(5 Pt 1):809. - PubMed
    1. Lucey J F. The future demise of exchange transfusions for neonatal hyperbilirubinemia. Dev Med Child Neurol. 1968;10(4):521. - PubMed

LinkOut - more resources